Diagnostic value of fibrinogen to prealbumin ratio and gamma-glutamyl transpeptidase to platelet ratio in the progression of AFP-negative hepatocellular carcinoma.
AFP-negative hepatocellular carcinoma
Diagnostic
Fibrinogen to prealbumin ratio
Gamma-glutamyl transpeptidase to platelet ratio
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
12
2019
accepted:
29
02
2020
entrez:
20
3
2020
pubmed:
20
3
2020
medline:
20
3
2020
Statut:
epublish
Résumé
This study aimed to comprehensively assess the diagnostic value of fibrinogen to prealbumin ratio (FPR) and gamma-glutamyl transpeptidase to platelet ratio (GPR) as single markers or in combination in patients with alpha-fetoprotein-negative (AFP-negative) hepatocellular carcinoma (HCC). A total of 199 healthy controls and 515 AFP-negative patients were enrolled in this study, including 180 HCC inpatients, 151 liver cirrhosis (LC) patients, and 184 chronic hepatitis (CH) cases. Mann-Whitney U or Kruskal-Wallis H test were used to analyze differences between groups in laboratory parameters and clinicopathological features. The diagnostic value of FPR and GPR, alone or in combination, in AFP-negative HCC (AFP-NHCC) patients was determined via a receiver operating characteristic (ROC) curve. The levels of FPR and GPR were gradually increased in the development of AFP-NHCC and positively correlated with the tumor size and Barcelona Clinic Liver Cancer (BCLC) stages. Moreover, GPR was associated with Edmondson-Steiner grades. After univariate logistic regression analysis, FPR and GPR remained independent predictors of adverse outcomes. The combination of FPR and GPR had a good ability to detect AFP-NHCC from the control group (area under curve [AUC] = 0.977), AFP-negative CH (AUC = 0.745), and AFP-negative LC (AUC = 0.666). FPR combined with GPR possessed a larger area (0.943, 0.971) and sensitivity (87.50%, 89.81%) than FPR or GPR alone for differentiating AFP-NHCC with tumor size < 3 cm or at the BCLC-A stage. The pretreatment levels of FPR and GPR played vital roles in the development of AFP-NHCC, especially in patients with early or small AFP-NHCC.
Sections du résumé
BACKGROUND
BACKGROUND
This study aimed to comprehensively assess the diagnostic value of fibrinogen to prealbumin ratio (FPR) and gamma-glutamyl transpeptidase to platelet ratio (GPR) as single markers or in combination in patients with alpha-fetoprotein-negative (AFP-negative) hepatocellular carcinoma (HCC).
METHODS
METHODS
A total of 199 healthy controls and 515 AFP-negative patients were enrolled in this study, including 180 HCC inpatients, 151 liver cirrhosis (LC) patients, and 184 chronic hepatitis (CH) cases. Mann-Whitney U or Kruskal-Wallis H test were used to analyze differences between groups in laboratory parameters and clinicopathological features. The diagnostic value of FPR and GPR, alone or in combination, in AFP-negative HCC (AFP-NHCC) patients was determined via a receiver operating characteristic (ROC) curve.
RESULTS
RESULTS
The levels of FPR and GPR were gradually increased in the development of AFP-NHCC and positively correlated with the tumor size and Barcelona Clinic Liver Cancer (BCLC) stages. Moreover, GPR was associated with Edmondson-Steiner grades. After univariate logistic regression analysis, FPR and GPR remained independent predictors of adverse outcomes. The combination of FPR and GPR had a good ability to detect AFP-NHCC from the control group (area under curve [AUC] = 0.977), AFP-negative CH (AUC = 0.745), and AFP-negative LC (AUC = 0.666). FPR combined with GPR possessed a larger area (0.943, 0.971) and sensitivity (87.50%, 89.81%) than FPR or GPR alone for differentiating AFP-NHCC with tumor size < 3 cm or at the BCLC-A stage.
CONCLUSIONS
CONCLUSIONS
The pretreatment levels of FPR and GPR played vital roles in the development of AFP-NHCC, especially in patients with early or small AFP-NHCC.
Identifiants
pubmed: 32190001
doi: 10.1186/s12935-020-1161-y
pii: 1161
pmc: PMC7066792
doi:
Types de publication
Journal Article
Langues
eng
Pagination
77Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors report no competing interests.
Références
Protoplasma. 2017 Mar;254(2):911-920
pubmed: 27525410
Future Oncol. 2019 Jan;15(1):13-22
pubmed: 30139267
J Gastroenterol Hepatol. 2017 Jun;32(6):1221-1229
pubmed: 27859587
J Viral Hepat. 2018 May;25(5):581-589
pubmed: 29230907
Drug Discov Ther. 2014 Jun;8(3):134-8
pubmed: 25031046
World J Gastroenterol. 2015 Oct 7;21(37):10573-83
pubmed: 26457017
Oncotarget. 2016 Mar 22;7(12):15230-42
pubmed: 26885692
PLoS One. 2015 Oct 06;10(10):e0140067
pubmed: 26441340
Onco Targets Ther. 2016 Apr 12;9:2099-109
pubmed: 27110127
Contemp Nurse. 2018 Dec;54(6):561-577
pubmed: 30176764
PLoS One. 2012;7(12):e51165
pubmed: 23227248
Hepatobiliary Pancreat Dis Int. 2018 Dec;17(6):487-495
pubmed: 30257796
Ann N Y Acad Sci. 2001;936:406-25
pubmed: 11460495
ANZ J Surg. 2018 Dec;88(12):1328-1332
pubmed: 29534342
Clin Chem. 1982 Jul;28(7):1706-7
pubmed: 6805982
Abdom Radiol (NY). 2018 Jan;43(1):13-25
pubmed: 28647765
Oncotarget. 2017 Sep 6;8(43):75195-75205
pubmed: 29088857
Oncology. 2019;96(1):25-32
pubmed: 30336489
Int J Hyperthermia. 2018;35(1):500-504
pubmed: 30204007
Nutr Cancer. 2019 Sep 11;:1-8
pubmed: 31507226
Scand J Clin Lab Invest Suppl. 2016;245:S70-6
pubmed: 27438343
Anal Bioanal Chem. 2018 Dec;410(30):7965-7977
pubmed: 30397756
Ann Hepatol. 2019 Jan - Feb;18(1):58-67
pubmed: 31113610
Anticancer Res. 2009 Jul;29(7):2531-4
pubmed: 19596924
Oncotarget. 2017 Jul 22;8(35):59257-59267
pubmed: 28938634
Int J Oncol. 2015 Aug;47(2):543-54
pubmed: 26058824
Int J Biol Sci. 2019 Jan 1;15(1):221-228
pubmed: 30662361
Medicine (Baltimore). 2017 Apr;96(17):e6694
pubmed: 28445272
Hepatology. 1990 Dec;12(6):1420-32
pubmed: 1701754
Eur J Gastroenterol Hepatol. 2011 Sep;23(9):787-93
pubmed: 21730869
Cancer Manag Res. 2018 Jul 19;10:2151-2161
pubmed: 30050325
Hepatology. 2011 Mar;53(3):1060-1; author reply 1061-2
pubmed: 21374678
Onco Targets Ther. 2015 Dec 31;9:123-9
pubmed: 26770061
Pathol Oncol Res. 2019 Oct 2;:
pubmed: 31578661
Nat Commun. 2016 Aug 24;7:12598
pubmed: 27553854
World J Gastroenterol. 2017 May 14;23(18):3228-3239
pubmed: 28566882
Blood. 2000 Dec 1;96(12):3772-8
pubmed: 11090059
Int J Biol Markers. 2014 Dec 09;29(4):e395-402
pubmed: 24832180
PLoS One. 2016 Apr 12;11(4):e0153227
pubmed: 27070780
Gut. 2016 Aug;65(8):1369-76
pubmed: 26109530
Int J Clin Pract. 2015 Oct;69(10):1121-8
pubmed: 26133088
Medicine (Baltimore). 2019 Mar;98(9):e14749
pubmed: 30817633
Liver Int. 2012 Aug;32(7):1053-63
pubmed: 22432445
J Surg Res. 2018 Nov;231:403-410
pubmed: 30278960
Hepatology. 2011 Sep 2;54(3):1113
pubmed: 21520202
World J Hepatol. 2015 Jun 18;7(11):1530-40
pubmed: 26085912
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593